-+ 0.00%
-+ 0.00%
-+ 0.00%

Amylyx Publishes Presentation on Avexitide Phase 3 LUCIDITY Trial Results

PUBT·11/15/2026 17:03:11
Listen to the news
Amylyx Publishes Presentation on Avexitide Phase 3 LUCIDITY Trial Results
  • Amylyx Pharmaceuticals published its ObesityWeek presentation detailing pivotal Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia.
  • Avexitide met the primary endpoint, reducing the composite rate of level 2/3 hypoglycemic events by 55% versus placebo; p=0.0000034.
  • Model-adjusted weekly event rates were 0.55 with avexitide versus 1.24 with placebo during the 16-week double-blind period.
  • The trial randomized 78 participants; primary endpoint results were consistent across prespecified sensitivity analyses and evaluated subgroups.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief on November 15, 2026, and is solely responsible for the information contained therein.